[1]赵嘉莉,张慧敏.枯草杆菌二联活菌肠溶胶囊治疗溃疡性结肠炎疗效观察[J].新乡医学院学报,2016,33(11):983-986.[doi:10.7683/xxyxyxb.2016.11.013]
　ZHAO Jia-li,ZHANG Hui-min.Effect of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules on ulcerative colitis[J].Journal of Xinxiang Medical University,2016,33(11):983-986.[doi:10.7683/xxyxyxb.2016.11.013]
点击复制

枯草杆菌二联活菌肠溶胶囊治疗溃疡性结肠炎疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
33
期数:
2016年11
页码:
983-986
栏目:
临床研究
出版日期:
2016-11-05

文章信息/Info

Title:
Effect of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules on ulcerative colitis
作者:
赵嘉莉1; 张慧敏2
（1.呼和浩特市第一医院消化内科，内蒙古　呼和浩特　010030；2.内蒙古自治区人民医院消化内科，内蒙古　呼和浩特　010070）
Author(s):
ZHAO Jia-li1; ZHANG Hui-min2
(1.Department of Gastroenterology,Hohhot First Hospital,Hohhot 010030,Inner Mongolia Autonomous Region,China;2.Department of Gastroenterology,Inner Mongolia Autonomous Region People′s Hospital,Hohhot 010070,Inner Mongolia Autonomous Region,China)
关键词:
溃疡性结肠炎; 枯草杆菌二联活菌肠溶胶囊; 红细胞沉降率; C-反应蛋白
Keywords:
ulcerative colitis; live combined bacillus subtilis and enterococcus faecium enteric-coated capsules; erythrocyte sedimentation rate; C-reactive protein
分类号:
R57
DOI:
10.7683/xxyxyxb.2016.11.013
文献标志码:
A
摘要:
目的　研究枯草杆菌二联活菌肠溶胶囊治疗溃疡性结肠炎（UC）的临床效果。方法　将62例轻、中度UC患者按随机对照原则分为观察组和对照组，每组31例。对照组患者采用美沙拉嗪肠溶片治疗，观察组患者在美沙拉嗪肠溶片治疗基础上加用枯草杆菌二联活菌肠溶胶囊，疗程为6个月。观察2组患者治疗前、后结肠镜下表现、肠黏膜病理组织学表现以及外周血红细胞沉降率（ESR）、血清C-反应蛋白（CRP）水平变化情况，并比较2组患者临床治疗效果。结果　治疗前2组患者结肠镜下表现、肠黏膜组织病理分级、外周血ESR及血清CRP水平比较差异均无统计学意义（P>0.05）。治疗6个月后，观察组患者总有效率为93.5%（29/31），较对照组的74.2%（23/31）显著提高（P<0.05）。2组患者治疗后结肠镜下表现及肠黏膜组织病理分级均较治疗前明显减轻（P<0.05），且治疗后观察组较对照组减轻更明显（P<0.05）。治疗后2组患者外周血ESR和血清CRP水平均较治疗前显著降低（P<0.05），且观察组患者较对照组下降更明显（P<0.05）。结论　枯草杆菌二联活菌肠溶胶囊治疗UC可提高其临床疗效，外周血ESR和血清CRP可作为反映UC炎症活动的指标，协助评估药物治疗效果。
Abstract:
Objective　To investigate the effect of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules on ulcerative colitis(UC).Methods　A total of 62 cases of mild and moderate UC were randomly divided into observation group and control group,31 cases in each group.The patients in control group were treated with mesalazine slow release tablets,and the patients in observation group were treated with mesalazine slow release tablets and live combined bacillus subtilis and enterococcus faecium enteric-coated capsules for six months.The characteristic of colon under colonoscope,intestinal mucosa pathological changes,peripheral blood erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) changes were observed in the two groups before and after treatment.The clinical therapeutic effect was compared between the two groups.Results　There was no significant difference in the characteristic of colon under colonoscope,pathological grading of intestinal mucosa,peripheral blood ESR and serum CRP level between the two groups before treatment(P>0.05).Six months after treatment,the total effective rate in observation group and control group was 93.5%(29/31) and 74.2%(23/31) respectively,the total effective rate in observation group was significantly higher than that in control group(P<0.05).The characteristic of colon under colonoscope and pathological grading of intestinal mucosa after treatment were significantly improved than those before treatment in the two groups(P<0.05);and the improvement in observation group was more(P<0.05).The peripheral blood ESR and serum CRP level after treatment were significantly lower than those before treatment in the two groups(P<0.05),and the decrease was more in observation group(P<0.05).Conclusion　Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules for treating UC can improve the clinical efficacy.ESR and serum CRP in peripheral blood can be used as an index to reflect the inflammatory activity of UC,which may assist the evaluation of the effect of drug treatment.

参考文献/References:

［1］　NELL S,SUERBAUM S,JOSENHANS C.The impact of the microbiota on the pathogenesis of IBD:lessons from mouse infection models［J］.Nat Rev Microbiol,2010,8(8):564-577.
［2］　HANSEN R,THOMSON J M,EL-OMAR E M,et al.The role of infection in the aetiology of inflammatory bowel disease［J］.J Gastroenterol,2010,45(3):266-276.
［3］　洪娜,于成功.肠道菌群在炎症性肠病发生中的作用［J］.胃肠病学,2011,16(11):692-695.
［4］　中华医学会消化病分会炎症性肠病协作组.中国炎症性肠病诊断治疗规范的共识意见［J］.中华内科杂志，2008,47(1)：73-79.
［5］　RUTGEERTS P,SANDBORN W J,FEAGAN B G,et al.Infliximab for induction and maintenance therapy for ulcerative colitis［J］.N Engl J Med,2005,353(23):246-276.
［6］　HUGOT J P,CHAMAILLARD M,ZOUALI H,et al.Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn′s disease［J］.Nature,2001,411（6837）:599-603.
［7］　MATSUOKA K,KANAI T.The gut microbiota and inflammatorybowel disease［J］.Semin Immunopathol,2015,37(1):47-55.
［8］　COMITO D,CASCIO A,ROMANO C.Microbiota biodiversity in inflammatory bowel disease［J］.Ital J Pediatr,2014,40:32.
［9］　BRUNER S D,JOBIN C.Intestinal microbiota in inflammatory bowel disease and carcinogenesis:implication for therapeutics［J］.Clin Pharmacol Ther,2016,99(6):585-587.
［10］　FULLER R.Probiotics in man and animals［J］.J Appl Bacteriol,1989,66(5):365-378.
［11］　LAPCHINSKAIA A V,ZASLAVSKIA P L,SHENDEROV B A,et al.Effect of cephalexin on the colonization resistance of the large intestine in experimental animals［J］.Antibiot Khimioter,1989,34(2):116-120.
［12］　KONDRAKOVA O A,MULIAR E A,VOROPAEVA E A,et al.Oral cavity microflora in patients with non-specific ulcerative colitis and Crohn′s disease［J］.Zh Mikrobiol Epidemiol Immunobiol,2009(1):71-76.
［13］　汤绍辉，冯淑芬，姚艳芳，等.益生菌对溃疡性结肠炎诱导缓解及维持治疗疗效的meta分析［J］.解放军医学杂志，2010,35(5):521-525.
［14］　柯贤胜.美沙拉嗪对溃疡性结肠炎患者血清白细胞介素-6、白细胞介素-8及肿瘤坏死因子-α的影响［J］.新乡医学院学报,2012,29(12):950-957.
［15］　胡正波，陈路佳，滕飞，等.美常安联合常规治疗对溃疡性结肠炎的系统评价［J］.药物研究，2013,22（7）：3-7.
［16］　DROUAULT-HOLOWACZ S,FOLIGNE B,DENNIN V,et al.Anti-inflaxnmatory potential of the probiotic dietary supplement lacti-biane tolerance:in vitro and in vivo considerations［J］.Clin Nutr,2006,25(6):994-1003.
［17］　MADSEN K L,DOYLE J S,JEWELL L D,et al.Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice［J］.Gastroenterology,1999,116(5):1107-1114.
［18］　NG S C,HART A L,KAMM M A,et al.Mechanisms of action of probiotics:recent advances［J］.Inflamm Bowel Dis,2009,15(2):300-310.
［19］　刘丹，周磊.溃疡性结肠炎患者血小板、C反应蛋白、血沉的临床意义［J］.中国现代药物应用，2015,9(18):13-15.

相似文献/References:

[1]侯再恩.肠炎平治疗溃疡性结肠炎58例[J].新乡医学院学报,2003,20(05):376.
[2]侯再恩.肠炎平治疗溃疡性结肠炎58 例[J].新乡医学院学报,2003,20(05):376.
[3]张小毅,刘瑞丽,韩效林,等.愈疡液治疗大鼠溃疡性结肠炎的实验研究[J].新乡医学院学报,2003,20(01):021.
[4]张小毅,刘瑞丽,韩效林,等.愈疡液治疗大鼠溃疡性结肠炎的实验研究[J].新乡医学院学报,2003,20(01):021.
[5]柯贤胜.美沙拉嗪对溃疡性结肠炎患者血清白细胞介素-6、白细胞介素-8及肿瘤坏死因子-α的影响 [J].新乡医学院学报,2012,29(12):950.
[6]张　伟,杨银利,张　林,等.青柏溃结汤灌肠对溃疡性结肠炎大肠湿热证患者结肠黏膜愈合及血清炎性因子水平的影响[J].新乡医学院学报,2018,35(6):474.[doi:10.7683/xxyxyxb.2018.06.006]
　ZHANG Wei,YANG Yin-li,ZHANG Lin,et al.Effect of Qingbaikuijietang enema on colonic mucosa healing and serum inflammatory factors in patients with ulcerative colitis and large intestine damp-heat syndrome[J].Journal of Xinxiang Medical University,2018,35(11):474.[doi:10.7683/xxyxyxb.2018.06.006]
[7]杜鹏程,韩　璠,谷九莲.溃疡性结肠炎患者血清单核细胞趋化蛋白-1、高迁移率族蛋白B1、肿瘤坏死因子-α、白细胞介素-6和白细胞介素-10水平与肠道菌群的相关性[J].新乡医学院学报,2021,38(4):370.[doi:10.7683/xxyxyxb.2021.04.016]
　DU Pengcheng,HAN Fan,GU Jiulian.Correlation between serum monocyte chemoattractant protein-1,high mobility group protein B1,tumor necrosis factor-α,interleukin-6,interleukin-10 levels and intestinal flora in patients with ulcera-tive colitis[J].Journal of Xinxiang Medical University,2021,38(11):370.[doi:10.7683/xxyxyxb.2021.04.016]
[8]于佳卉,毛光兰,王庆志,等.沉默信号调节蛋白6在溃疡性结肠炎小鼠结肠组织中的表达及意义[J].新乡医学院学报,2021,38(9):806.[doi:10.7683/xxyxyxb.2021.09.002]
　YU Jiahui,MAO Guanglan,WANG Qingzhi,et al.Expression and role of silent information regulator 6 in colon tissues of mice with ulcerative colitis[J].Journal of Xinxiang Medical University,2021,38(11):806.[doi:10.7683/xxyxyxb.2021.09.002]
[9]胡景岚.ω-3多不饱和脂肪酸和美沙拉嗪联合治疗对溃疡性结肠炎患者血清辅助性T细胞1及辅助性T细胞2细胞因子水平的影响[J].新乡医学院学报,2019,36(1):067.[doi:10.7683/xxyxyxb.2019.01.014]
　HU Jing-lan.Effect of ω-3 polyunsaturated fatty acid combined with mesalazine on the levels of serum helper T cell 1 and helper T cell 2 cytokines in patients with ulcerative colitis[J].Journal of Xinxiang Medical University,2019,36(11):067.[doi:10.7683/xxyxyxb.2019.01.014]
[10]朱佳丽,鲁素彩.小檗碱治疗溃疡性结肠炎研究进展[J].新乡医学院学报,2022,39(2):187.[doi:10.7683/xxyxyxb.2022.02.018]
　ZHU Jiali,LU Sucai.Research progress of berberine in the treatment of ulcerative colitis[J].Journal of Xinxiang Medical University,2022,39(11):187.[doi:10.7683/xxyxyxb.2022.02.018]

更新日期/Last Update: 2016-11-05